Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center.

Journal Article (Journal Article)

Sézary syndrome (SS) is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma, with a median overall survival (OS) rate of 2-4 years. Few studies have described the clinical outcome of SS patients since 2012. We retrospectively analyzed 70 patients diagnosed with SS treated at a high-volume tertiary cancer center between 2000 and 2018. Overall survival at 1 and 5 years was 84.1% and 50.7%, respectively. Univariate analyses identified older age (>65 years) and male sex as poor prognostic factors. Five patients presented with circulating large granular lymphocytic proliferation and had a favorable prognosis. Targeted therapies were effective in treating refractory/relapsed SS patients with a durable response. Therapeutic advancements and the comprehensive treatments used in a multidisciplinary clinic improved OS rates.

Full Text

Duke Authors

Cited Authors

  • Zhang, Y; Seminario-Vidal, L; Varnadoe, C; Lu, Y; Dong, N; Salamanca, C; Whiddon, S; Bennett, J; Hargis, R; Liu, H; Montejo, M; Hussaini, M; Harro, C; Messina, J; Benson, K; Pinilla-Ibarz, J; Conejo-Garcia, J; Sokol, L

Published Date

  • January 2022

Published In

Volume / Issue

  • 63 / 1

Start / End Page

  • 109 - 116

PubMed ID

  • 34467825

Pubmed Central ID

  • PMC9167451

Electronic International Standard Serial Number (EISSN)

  • 1029-2403

Digital Object Identifier (DOI)

  • 10.1080/10428194.2021.1971218


  • eng

Conference Location

  • United States